Genitourinary cancers are malignancies involving organs of the male reproductive or urinary systems of men or woman. Genitourinary cancers include adrenal, bladder, kidney, penile, prostate, and testicular cancers. There are a broad range of treatment regimens used to treat genitourinary cancers depending on factors such as the type and stage of disease and the patient's overall health and comorbidities.
Description: Join this two-part webinar to learn how capillary electrophoresis (CE) complements sequencing technologies, such as next generation sequencing, that are being used by cancer res...
Description: Join this two-part webinar to learn when capillary electrophoresis is an ideal choice relative to other various sequencing technologies – such as next generation sequencin...
Dr Philippe Taniere – Understanding biomarker testing for immunotherapy; PD-L1 (Programmed Death-Ligand 1) expression, Mismatch Repair (MMR) testing and the importance of Microsatellit...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
Learning Objectives: 1. Define applications of approved and experimental (multiplexing IF) biomarker assessment in Immuno-Oncology 2. Define bottlenecks and areas of improvement to current t...
Platinum-based chemotherapy has been the cornerstone for treating metastatic urothelial cancer, which compromises the majority of bladder cancer. While urothelial cancer is chemosensitive, p...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
DATE: December 5th, 2017TIME: 6:00AM PTAndrogen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Nov...
DATE: August 11, 2016
TIME: 11:00AM PST, 2:00PM ET, 7:00PM GMT
The central dogma that forms the backbone of molecular biology is that DNA codes for RNA (transcription) which then c...
The management of prostate cancer (PCa) continues to evolve and does so at a rapid rate. Research and technological developments continue to refine our definitions and management of this comp...
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
Description: Join this two-part webinar to learn how capillary electrophoresis (CE) complements sequencing technologies, such as next generation sequencing, that are being used by cancer res...
Description: Join this two-part webinar to learn when capillary electrophoresis is an ideal choice relative to other various sequencing technologies – such as next generation sequencin...
Dr Philippe Taniere – Understanding biomarker testing for immunotherapy; PD-L1 (Programmed Death-Ligand 1) expression, Mismatch Repair (MMR) testing and the importance of Microsatellit...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
Immune therapy approaches are being used in many different solid cancers today including clear cell renal carcinoma (mccRCC) and metastatic prostate adenocarcinoma. Over the past few years i...
Immune checkpoint therapies targeting the CTLA-4 and PD-(L)1 pathways have been largely clinically disappointing for patients with prostate cancer. This can be attributed to the highly immun...
Learning Objectives: 1. Define applications of approved and experimental (multiplexing IF) biomarker assessment in Immuno-Oncology 2. Define bottlenecks and areas of improvement to current t...
Platinum-based chemotherapy has been the cornerstone for treating metastatic urothelial cancer, which compromises the majority of bladder cancer. While urothelial cancer is chemosensitive, p...
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events an...
DATE: December 5th, 2017TIME: 6:00AM PTAndrogen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Nov...
DATE: August 11, 2016
TIME: 11:00AM PST, 2:00PM ET, 7:00PM GMT
The central dogma that forms the backbone of molecular biology is that DNA codes for RNA (transcription) which then c...
The management of prostate cancer (PCa) continues to evolve and does so at a rapid rate. Research and technological developments continue to refine our definitions and management of this comp...
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
Opens in a new windowOpens an external siteOpens an external site in a new window